We founded LuMiAL Bio to transform loss into hope by developing better biological therapies
for cancer and autoimmune diseases, so that no one else has to face these diseases without
options. We are here to bring innovation, compassion, and cures to patients before it is
too late.
AI-Driven Discovery of Next-Generation Therapeutics
LuMiAL Bio addresses the high failure rates and lengthy development timelines associated with traditional
antibody and ligand–receptor binder discovery in oncology and immune-mediated diseases.
The company is developing an advanced AI-driven computational platform designed to identify high-affinity
binder inhibitors targeting cancer-specific proteins and key mediators of autoimmune disorders. By
significantly narrowing the biological “search space,” this technology accelerates target validation
and enables the development of transformative, life-saving therapies.
Founders
Miguel E Moreno-Garcia, PhD
Co-Founder
Miguel Moreno-Garcia, Ph.D., brings over 20 years of experience in immunology and drug discovery
across academia and the biopharmaceutical industry. Miguel earned his PhD in Cell Biology from
CINVESTAV, with training at the Trudeau Institute and UCLA School of Medicine. Miguel completed
postdoctoral fellowships at the University of Washington and Seattle Children’s Research Institute.
Miguel has led discovery programs at Boehringer Ingelheim and Pfizer, advancing biotherapeutics
that target immune-modulatory pathways in autoimmune disease, oncology, and fibrosis, with deep
expertise in B-cell biology and biomarker strategy.
Lucrecia Marquez-Rosado, M.D., Ph.D., is a physician-scientist with over 20 years of experience
in oncology, immunology, and drug discovery in both academia and biotech. She completed clinical
training at the Salvador Zubirán National Institute, earned a Ph.D. in Cell Biology from CINVESTAV,
and finished a postdoctoral fellowship at the Fred Hutchinson Cancer Research Center. Before
co-founding LuMiAL Bio, she held scientific roles at Boehringer Ingelheim, SIBTECH, and Nurix
Therapeutics, where she led cross-functional teams involved in translational research programs.
Lucrecia brings extensive expertise in targeted protein degraders and small-molecule discovery,
biomarker and disease-positioning strategies, and progressing therapeutic programs from target
validation through the discovery pipeline.
LuMiAL Bio presentation by Co-Founder Dr. Lucrecia Marquez-Rosado, delivered at the 13th Annual Clinical Trials in Oncology West Coast 2026 conference. A strategic guide for biotech founders and oncology clinical teams on how to align trial design with today's investor priorities. The presentation unpacks the 2026 oncology investment landscape, shows how to build a compelling investor value narrative, and maps the networking platforms and partnerships that turn early science into funded programs.
LuMiAL Bio webinar presentation by Co-Founder Dr. Miguel E. Moreno-Garcia, delivered for the Sino Biological BioTalk series. Covers a novel antibody class for degrading disease-associated extracellular proteins and the AI-driven discovery workflow behind it.
LuMiAL Bio presented the talk “AI for Antibody-Mediated Protein Silencing: What is Possible Today.” AiPAT 2025 Symposium is a leading event focused on the intersection of AI and the discovery and development of biologics. It brings together researchers and industry teams to share advances in protein/antibody design, screening, developability, and manufacturing enabled by AI/ML.
LuMiAL Bio was invited to present a poster highlighting our AI-enabled antibody engineering and DegrAb™ platform for targeted protein silencing, discussing partnership opportunities to accelerate next steps. The MBC BioLabs Oncology Innovation Forum convenes founders, scientists, investors, and partners to spotlight emerging cancer technologies and translational breakthroughs. Sessions and poster showcases focus on platform innovation, preclinical validation, and pathways to clinical impact—creating a high-signal venue for collaboration and feedback.
LuMiAL Bio’s Co-Founders served as chairperson and panel moderator for the discussion, “Antibody Therapeutics: Advancements, Challenges, and Future Directions.” The session explores how next-generation antibody modalities are reshaping discovery and development. Nexus Conferences are recognized as leader-level forums for drug discovery and development. Programming spotlights cutting-edge science and scalable platform execution, with sessions led by experts across biotech, pharma, and academia.
